Table 2.
Current status in mRNA therapeutics development
| Therapeutic areas | Therapeutic strategy | Indication | Company |
|---|---|---|---|
| Infectious diseases | Vaccine | COVID-19 | Moderna, BioNTech, Curevac, Sirnaomics, eTheRNA, Walvax, Translate Bio, Ethris, Arcturus, Tiba, Acuitas, StemiRNA, RNACure, Abogen, Precision NanoSystems, Longuide Limited Lab |
| Influenza | Moderna, BioNTech, Curevac, Sirnaomics, Arcturus, Tiba, StemiRNA, RNACure | ||
| RSV infection | Moderna, Curevac, Ethris, RNACure | ||
| HIV infection | Moderna, BioNTech, eTheRNA, Argos | ||
| Rabies | Curevac, Precision NanoSystems | ||
| HPV infection | Sirnaomics, eTheRNA, StemiRNA | ||
| Malaria | BioNTech, Curevac, eTheRNA | ||
| EBV infection | Moderna, StemiRNA | ||
| Tuberculosis | BioNTech, StemiRNA | ||
| CMV infection | Moderna, Rhegen | ||
| Herpes zoster | Abogen | ||
| Zika virus infection | Moderna | ||
| HBV infection | Sirnaomics | ||
| Yellow fever | Curevac | ||
| PIV infection | Moderna | ||
| hMPV infection | Moderna | ||
| Rotavirus infection | Curevac | ||
| Nipah virus infection | Moderna | ||
| Antibody | COVID-19 | BioNTech, Sirnaomics | |
| Chikungunya virus Infection | Moderna | ||
| Gene editing | HIV | Sangamo | |
| Oncology | Vaccine | Melanoma | BioNTech, Curevac, eTheRNA |
| NSCLC | BioNTech, Sirnaomics | ||
| Cervical cancer | Sirnaomics, eTheRNA | ||
| Breast cancer | Sirnaomics | ||
| Ovarian cancer | BioNTech | ||
| Liver cancer | Sirnaomics | ||
| Gastric cancer | eTheRNA | ||
| Pancreatic cancer | Sirnaomics | ||
| Colorectal cancer | BioNTech, Sirnaomics | ||
| Bladder cancer | Sirnaomics | ||
| Prostate cancer | BioNTech | ||
| Head and neck cancer | BioNTech, Curevac | ||
| Adenoidcystic carcinoma | Curevac | ||
| cSCC | Curevac, Sirnaomics | ||
| Basal cell cancer | Sirnaomics | ||
| Renal cell cancer | eTheRNA, Argos | ||
| AML | StemiRNA | ||
| Personal vaccine | Ambiguity | BioNTech, Argos, StemiRNA, RNACures, Rhegen, Abogen | |
| CAR-T | Pancreatic cancer | BioNTech, | |
| Antibody | Pancreatic cancer | BioNTech, | |
| Genetic diseases | Protein replacement | Cystic fibrosis | Moderna, Translate Bio, Arcturus |
| Propionic acidemia | Moderna | ||
| Methylmalonic acidemia | Moderna | ||
| GSD1a | Moderna | ||
| Phenylketonuria | Moderna | ||
| CN-1 | Moderna | ||
| OTC | Arcturus | ||
| Hemophilia | Sirnaomics | ||
| Autoimmune disorders | Protein replacement | Ambiguity | Moderna, eTheRNA, Tiba |
| Metabolic disorders | Protein replacement | Type 2 diabetes | Moderna |
| Cardiovascular disease | Protein replacement | Hypercholesterolemia | Sirnaomics |
| Myocardial ischemia | Moderna | ||
| Fibrosis | Protein replacement | Hypertrophic scarring | Sirnaomics |
| Liver fibrosis | Sirnaomics | ||
| Lung fibrosis | Sirnaomics | ||
| Primary sclerosing cholangitis | Sirnaomics | ||
| Anemia | In-Cell-Art |